AEZS-131
/ COSCIENS Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 02, 2012
AEZS-131 – A highly selective ERK-inhibitor: Characterization and preclinical testing in triple negative breast cancer (TNBC)
(SABCS 2011)
- AEZS-131 selectively inhibited ERK with an IC50<4nM; Phosphorylation of Rsk-1 the cellular substrate of ERK was inhibited with an IC 50 of 158 nM; AEZS-131 induced cell cycle arrest in G1 dose-dependently and cleavage of PARP
Preclinical-other • Breast Cancer
1 to 1
Of
1
Go to page
1